<DOC>
	<DOC>NCT01285089</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this prospective, observational study are to describe the different clinical practice and detailed haemostatic management of activated recombinant human factor VII (NovoSeven®) in patients with acquired haemophilia in France. The secondary aim is to assess the primary haemostasis disorder associated with the coagulation disorders, if available.</brief_summary>
	<brief_title>Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Diagnosed with acquired haemophilia Treated with activated recombinant human factor VII as first line treatment Treated with activated recombinant human factor VII after January 2011 Patients with first diagnosis before january 2010 and having a relapse after january 2011 Known hypersensitivity to NovoSeven®, or to mouse, hamster or bovine protein</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>